Drug Database
Back to search

Poland· PL-100112606

Pegasys

A peginterferon alfa-2a product containing peginterferonum alfa-2a, registered in Poland by pharmaand GmbH. The same ATC class is registered in 14 of our 19 countries.

ATC L03AB11

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedPegasysATCL03AB11REGISTER NO.PL-100112606PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about peginterferonum alfa-2aAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Peginterferon alfa-2a is registered in 14 of 19 countries.

Countries holding a registration under ATC L03AB11 (peginterferon alfa-2a), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search peginterferon alfa-2a products by name

Peginterferon alfa-2a · ATC L03AB11

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Peginterferonum alfa-2a
Manufacturer
pharmaand GmbH
Country
Poland (PL)
ATC code
L03AB11
ATC class
Peginterferon alfa-2a
Defined daily dose
26 mcg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990984619
  • gtin
    05909990984626

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

201 interactions on record for peginterferon alfa-2a.

Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check peginterferon alfa-2a against other medicinesHow interaction checks work

Peginterferon alfa-2a · interactions on record

201 records

  • 35 severe
  • 163 moderate
  • 3 minor

Most severe, free to view

  • EltrombopagB02BX05severe
  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • TelbivudineJ05AF11severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Peginterferon alfa-2a in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All peginterferon alfa-2a products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Pegasys
  • Liechtenstein · Pegasys
  • Norway · Pegasys

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/09d38153-908a-4072-9ad0-b22712946856
GET /v1/drugs/09d38153-908a-4072-9ad0-b22712946856?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "180 mcg/ml",
  "packaging": "05909990984619 ¦ Rpz ¦ EU/1/02/221/003 ¦ 20296\n1 fiol. 1 ml\n05909990984626 ¦ Rpz ¦ EU/1/02/221/004 ¦ 20297\n4 fiol. 1 ml",
  "substance": "Peginterferonum alfa-2a 180 mcg",
  "common_name": "Peginterferonum alfa-2a",
  "pl_product_id": "100112606",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about peginterferon alfa-2a.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console